454181-69-2Relevant academic research and scientific papers
A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-Chloro-3- methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners
Mylari, Banavara L.,Armento, Sandra J.,Beebe, David A.,Conn, Edward L.,Coutcher, James B.,Dina, Michael S.,O'Gorman, Melissa T.,Linhares, Michael C.,Martin, William H.,Oates, Peter J.,Tess, David A.,Withbroe, Gregory J.,Zembrowski, William J.
, p. 6326 - 6339 (2007/10/03)
Discovery of a highly selective, potent, and safe non-carboxylic acid, non-hydantoin inhibitor of aldose reductase (AR) capable of potently blocking the excess glucose flux through the polyol pathway that prevails under diabetic conditions has been a long-standing challenge. In response, we did high-throughput screening of our internal libraries of compounds and identified 6-phenylsulfonylpyridazin-2H-3-one, 8, which showed modest inhibition of AR, both in vitro and in vivo. Initial structure-activity relationships concentrated on phenyl substituents and led to 6-(2,4-dichlorophenylsulfonyl)-2/f-pyridazin- 3-one, 81, which was more potent than 8, both in vitro and in vivo. Incorporation of extant literature findings with other aldose reductase inhibitors, including zopolrestat, resulted in the title inhibitor, 19m, which is one of the most potent and highly selective non-carboxylic acid, non-hydantoin inhibitors of AR yet described (IC50, 1 nM; ED 90 vs sciatic nerve sorbitol and fructose, respectively, 0.8 and 4.0 mg/kg). In rats, its oral bioavailability is 98% and it has a favorable plasma t1/2 (26 ± 3 h).
Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
-
, (2008/06/13)
This invention relates to novel sulfonyl pyridazinone compounds useful as aldose reductase inhibitors in the treatment or prevention of certain complications arising from diabetes mellitus, pharmaceutical compositions comprising the sulfonyl pyridazinone, pharmaceutical compositions comprising a combination of the sulfonyl pyridazinone together with a second pharmaceutical agent, therapeutic methods comprising the administration of the sulfonyl pyridazinone compounds, therapeutic methods comprising the administration of the sulfonyl pyridazinone compounds in combination with a second pharmaceutical agent and compounds useful as intermediates for preparing the sulfonyl pyridazinone compounds of this invention.
Therapies for tissue damage resulting from ischemia
-
, (2008/06/13)
This invention relates to therapeutic methods for treatment or prevention of tissue damage resulting from ischemia in mammals.
A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2-H-pyridazin-3-one
Mylari, Banavara L.,Armento, Sandra J.,Beebe, David A.,Conn, Edward L.,Coutcher, James B.,Dina, Michael S.,O'Gorman, Melissa T.,Linhares, Michael C.,Martin, William H.,Oates, Peter J.,Tess, David A.,Withbroe, Gregory J.,Zembrowski, William J.
, p. 2283 - 2286 (2007/10/03)
We report here on the discovery path that led to a structurally unprecedented non-hydantoin, non-carboxylic acid aldose reductase inhibitor, 24, which shows remarkably potent oral activity in normalizing elevated sorbitol levels and, more significantly, f
Sulfonyl pyridazinone compounds as therapeutic agents for ischemic tissue damage
-
, (2008/06/13)
This invention relates to therapeutic methods for treatment or prevention of tissue damage resulting from ischemia in mammals.
Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
-
Page 26, (2010/01/31)
Compounds of the formula (I): a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug, wherein R1, R2, X and Y are as defined in the claims are aldose reductase inhibitors useful in the treatment or p
